Home Gilead Announces Interim Phase 2 Results for GS-9973 in Previously...
 

Keywords :   


Gilead Announces Interim Phase 2 Results for GS-9973 in Previously...

2013-12-08 05:39:25| Biotech - Topix.net

Gilead Sciences, Inc. today announced interim results from a single-arm, open-label Phase 2 study evaluating GS-9973, an investigational oral inhibitor of spleen tyrosine kinase , for the treatment of patients with relapsed or refractory hematologic malignancies.

Tags: in results previously phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
28.06Tropical Depression Two Graphics
28.06Tropical Depression Two Public Advisory Number 1
28.06Summary for Tropical Depression Two (AT2/AL022024)
28.06Tropical Depression Two Forecast Advisory Number 1
28.06Tropical Depression Two Forecast Discussion Number 1
28.06Tropical Depression Two Wind Speed Probabilities Number 1
28.06Cattle producers celebrate Supreme Court decision to rein in administrative overreach
28.06Diversified Labeling Solutions expands RFID capabilities
More »